+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bipolar Depression - Market Insights, Epidemiology, and Market Forecast-2030

  • ID: 5135436
  • Drug Pipelines
  • October 2020
  • Region: Global
  • 227 pages
  • DelveInsight

FEATURED COMPANIES

  • Celon Pharma
  • COMPASS Pathways
  • Iltoo Pharma
  • Intra-cellular Therapies
  • NeuroRx
  • Otsuka Pharmaceutical
This ‘Bipolar Depression-Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Bipolar Depression market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Bipolar Depression market size from 2017 to 2030. The Report also covers current Bipolar Depression treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Bipolar Depression Disease Understanding and Treatment Algorithm

Bipolar Depression Overview

Bipolar disorder (BD), previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed). In manic episodes, a person can be very happy, irritable, or “up”, and there is a marked increase in activity level. Hypomanic episodes are also seen in patients and it is a less severe form of mania. In depressive episodes (bipolar depression), the patient might feel sad, indifferent, or hopeless, in combination with a very low activity level.

BD is divided mainly into fThe subtypes BD-I, BD-II, cyclothymic disorder, and bipolar disorder not otherwise specified (NOS). The classification is based on the characteristics of mood swings. The symptoms of BD can vary and individuals may have episodes of mania, depression, or mixed episodes. The depressive episodes usually last longer than mania and hypomania.

The symptoms of Bipolar Depression include feeling sad or anxious; restless; trouble concentrating or making decisions; trouble falling asleep, waking up too early, or sleeping too much; lack of interest; feeling hopeless or worthless, or thinking about death or suicide; unable to do even simple things, and talking very slowly, feeling like he/she has nothing to say, or forgetting a lot.

Bipolar Depression Diagnosis

There is no test available for the diagnosis, a psychiatrist can diagnose it based on the patient’s history and symptoms. Bipolar depression is often misdiagnosed as unipolar depression as long as manic episodes not appear. The diagnosis of bipolar depression can be made by the use of ICD-10 or DSM-5 manuals.

Bipolar Depression Treatment

The ultimate goal of treatment is to achieve as high as possible a level of psychosocial function and health-related quality of life. Bipolar Depression is highly recurrent, and sometimes medication needs to continue even if the patient feels well. The treatment has two phases: the acute phase and the maintenance phase. Acute-phase treatment is focused on the management of acute mood episodes, whereas maintenance-phase treatment is focused on preventing recurrences of acute episodes. Each phase is associated with specific treatment needs, and available pharmacotherapies have shown a difference in effectiveness according to the illness phase. The treatment of bipolar depression includes mood stabilizers, antipsychotics, antidepressants, antianxiety medications, and psychotherapy.

Bipolar Depression Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Bipolar Depression, Type-specific Diagnosed Prevalent Cases of Bipolar Depression and Severity-specific Diagnosed Prevalent Cases of Bipolar Depression scenario of Bipolar Depression in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Key Findings
  • As per the analysts, the total diagnosed prevalent population of Bipolar Depression in the 7MM was 1,857,545 in 2017.
  • The estimates show the highest diagnosed prevalence of Bipolar Depression in the United States with 740,715 cases.
  • Bipolar I and Bipolar II are the major subtypes of BD. In 2017, out of the total diagnosed prevalent population of 740,715 cases in the US for Bipolar Depression, 291,134 and 449,581 cases were contributed by Bipolar I disorder and Bipolar II disorder, respectively.
  • Based on the severity of the Bipolar Depression, total diagnosed prevalent cases are categorized into mild, moderate, and severe. In 2017, out of the total diagnosed prevalent population in the US for Bipolar Depression, 28,666 cases were mild, 158,735 cases were moderate, and 553,092 cases were severe.
Bipolar Depression Epidemiology

The epidemiology segment also provides the Bipolar Depression epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Bipolar Depression Drug Chapters

The drug chapter segment of the Bipolar Depression report encloses the detailed analysis of Bipolar Depression marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Bipolar Depression clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

Bipolar Depression Marketed Drugs

Vraylar (Cariprazine): Allergan (AbbVie)/Gedeon Richter

Vraylar is an oral capsule containing cariprazine as an active ingredient. It is approved in the US for schizophrenia, bipolar disorder, and bipolar depression. In the EU it is approved as Reagila for the treatment of schizophrenia. Cariprazine also received regulatory approval in Singapore and Thailand for the treatment of schizophrenia. The mechanism of action of cariprazine in schizophrenia and bipolar I disorder is unknown. However, the efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Cariprazine forms two major metabolites, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR), that have in vitro receptor binding profiles similar to the parent drug.

Latuda (Lurasidone Hydrochloride): Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)
Latuda is an oral tablet containing lurasidone hydrochloride as an active ingredient. It is approved in the US for bipolar depression in pediatric patients (10-17 years of age) and schizophrenic patients (adolescent and adult); given as monotherapy and adjunctive therapy in adult patients with bipolar depression. In the EU, it is approved for the treatment of schizophrenia, whereas in Japan, it is approved for both, schizophrenia and bipolar disorder.

The company is also conducting a phase IIII randomized, 6-week, multicenter, double-blind, placebo-controlled, flexible-dose, parallel-group study of lurasidone for the treatment of bipolar I depression in China. The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin Type 2 (5HT2A) receptor antagonism.

Bipolar Depression Emerging Drugs

Abilify: Otsuka Pharmaceutical

Abilify (aripiprazole) is indicated to treat the symptoms of schizophrenia, bipolar I disorder (manic depression), and major depressive disorder. It is available as a tablet and suspension for injection. Oral solution and intramuscular injection of Abilify is discontinued in the US. The mechanism of action of aripiprazole in schizophrenia or bipolar mania is unclear. However, the efficacy of aripiprazole could be mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. Otsuka Holding is currently evaluating Abilify (tablet) in phase III clinical trial as an adjunctive treatment in the treatment of major depressive episodes associated with bipolar I or II disorder.

Falkieri: Celon Pharma

Falkieri (Esketamine DPI/Esketamine dry powder Inhaler) is an esketamine formulation and acts as an NMDA antagonist. The antidepressant activity of ketamine is established recently, even though it is majorly used in anesthesia. Esketamine as in form S-enantiomer is pharmacologically 3-4 times more potent to R-enantiomer. The goal of the project is to develop an innovative and convenient formulation for the patients to use Esketamine. The molecule has received approval by US FDA in March 2019, under the brand name Spravato, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them. The US FDA granted this approval of Spravato to Janssen Pharmaceuticals. Janssen had received fast track and Breakthrough Therapy Designation for intranasal ESK in 2013 for treatment-resistant depression (TRD) and in 2016 for the treatment of the major depressive disorder (MDD) with an imminent risk of suicide. Celon Pharma is currently conducting the phase II trial in subjects with treatment-resistant Bipolar Depression (TRBD). It is the first such formulation, which targets both the unipolar and bipolar treatment-resistant depression. It is co-financed from the National Funds Research and Development Center. As plans, Celon Pharma is expecting the Breakthrough designation for bipolar depression and fast track designation for both the indications (TRD and bipolar depression), by 2020.

Zuranolone: Sage Therapeutics

Zuranolone (SAGE-217) is a once-daily, two-week therapy in development for the treatment of the major depressive disorder (MDD) and postpartum depression (PPD). It is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system and contributes significantly to regulating brain function. The Landscape Program is evaluating the potential of zuranolone as a rapid-acting, short-course oral treatment for PPD and MDD. It includes three completed pivotal efficacy studies evaluating zuranolone 30 mg in PPD (ROBIN Study) and MDD (MDD-201, MOUNTAIN Study), the results of which have been previously reported. In March 2020, after a Breakthrough Therapy guidance meeting with the US FDA, Sage Therapeutics announced plans to launch three additional studies of its investigational drug zuranolone. Results are expected in 2021.

Bipolar Depression Market Outlook

The ultimate goal of treatment is to achieve as high as possible a level of psychosocial function and health-related quality of life. BD is a highly recurrent disorder and sometimes medication needs to continue even if the patient feels well. The treatment has two phases: the acute phase and the maintenance phase. Acute-phase treatment is focused on the management of acute mood episodes (manic, hypomanic, or depressive). Maintenance-phase treatment is focused on preventing recurrences of acute episodes. Each phase is associated with specific treatment needs, and available pharmacotherapies have shown differential efficacy according to the illness phase. Most commonly mood stabilizers, antipsychotics, antidepressants, antianxiety medications, and psychotherapy is used.

In the United States, only fThe medications are approved for acute treatment of depressive episodes in the context of bipolar disorder: Symbyax (olanzapine-fluoxetine combination), Seroquel and Seroquel XR (quetiapine), Latuda (lurasidone), and Vraylar (cariprazine). Although older medications such as lithium also have modest effects in acute bipolar depression.

In October 2008, the US FDA approved once-daily Seroquel XR (quetiapine fumarate) Extended-Release Tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex. Seroquel XR and Seroquel are also approved in the EU for the prevention of recurrence of bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment.

Symbyax was the first drug approved by the US FDA for the acute treatment of bipolar depression in adults in 2003. Zyprexa, in combination with fluoxetine, is now approved for the same indication. Oral Zyprexa and fluoxetine in combination is indicated for the treatment of depressive episodes associated with bipolar I disorder, based on clinical studies. Zyprexa monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder.

The US FDA approved lurasidone (Latuda, Sunovion Pharmaceuticals Inc) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) in children and adolescents aged 10-17 years. In March 2020, Latuda was approved in Japan for the improvement of depressive symptoms in patients with bipolar disorder.

Recently, in May 2019, a new approval by FDA was made for bipolar depression. The US FDA approved a supplemental New Drug Application for Vraylar for the expanded treatment of depressive episodes associated with bipolar I disorder in adults. Vraylar (cariprazine), developed by Hungary-based Gedeon Richter Ltd. and licensed to Allergan, has also been approved in the US for treatment of manic or mixed episodes associated with bipolar I disorder in adults.

In short, efficacious pharmacologic options for managing the most prevalent and most disabling phases of bipolar disorder are extremely limited. Treatments that work in both phases of bipolar disorder are especially rare. New treatments are desperately needed.

Key Findings
  • The market size of Bipolar Depression in the 7MM was USD 762.83 million in 2017.
  • According to the estimates, the highest market size of Bipolar Depression was found in the United States, followed by France.
  • The market size of the United States in 2017 was found to be USD 431.04 million, and the market size of Japan was USD 60.75 million.
  • In the EU5, the highest market share of Bipolar Depression was in France, followed by Germany and the United Kingdom, and the least of Spain, in 2017.
  • The upcoming therapy, Abilify (Aripiprazole), is anticipated to enter the market by 2021 in the US, and 2022 in EU-5 and Japan. Other therapies that are expected to enter the market before 2024 are Lumateperone, NRX-100/NRX-101, and Zuranolone.
The United States Market Outlook

This section provides the total Bipolar Depression market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total Bipolar Depression market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Bipolar Depression market size and market size by therapies in Japan are provided.

Bipolar Depression Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Bipolar Depression market or expected to get launched in the market during the study period 2017-2030. The analysis covers the Bipolar Depression market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Bipolar Depression Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Bipolar Depression emerging therapies.

Reimbursement Scenario in Bipolar Depression

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, the publisher considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

The publisher performs competitive and market Intelligence analysis of the Bipolar Depression market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Bipolar Depression, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Bipolar Depression epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Bipolar Depression is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Bipolar Depression market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Bipolar Depression market.
Report Highlights
  • The robust pipeline with novel MOA and oral ROA, increasing prevalence, effectiveness of drugs as both mono and combination therapy will positively drive the Bipolar Depression market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Bipolar Depression R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Bipolar Depression. Launch of emerging therapies will significantly impact the Bipolar Depression market.
  • The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Bipolar Depression Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Bipolar Depression Pipeline Analysis
  • Bipolar Depression Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Bipolar Depression Report Key Strengths
  • 11 Years Forecast
  • 7MM Coverage
  • Bipolar Depression Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Bipolar Depression Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis
Key Questions

Market Insights:
  • What was the Bipolar Depression market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Bipolar Depression total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Bipolar Depression market size during the forecast period (2020-2030)?
  • At what CAGR, the Bipolar Depression market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Bipolar Depression market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the Bipolar Depression market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What is the disease risk, burden, and unmet needs of Bipolar Depression?
  • What is the historical Bipolar Depression patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Bipolar Depression at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Bipolar Depression?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Bipolar Depression during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of Bipolar Depression along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Bipolar Depression in the US and Europe?
  • What are the Bipolar Depression marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Bipolar Depression?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Bipolar Depression?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bipolar Depression therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Bipolar Depression and their status?
  • What are the key designations that have been granted for the emerging therapies for Bipolar Depression?
  • What are the 7MM historical and forecasted market of Bipolar Depression?
Reasons to buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Bipolar Depression.
  • To understand the future market competition in the Bipolar Depression market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Bipolar Depression in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Bipolar Depression market.
  • To understand the future market competition in the Bipolar Depression market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Celon Pharma
  • COMPASS Pathways
  • Iltoo Pharma
  • Intra-cellular Therapies
  • NeuroRx
  • Otsuka Pharmaceutical
1. Key Insights

2. Executive Summary of Bipolar Depression

3. Bipolar Depression Market Overview at a Glance
3.1. Market Share (%) Distribution of Bipolar Depression in 2017
3.2. Market Share (%) Distribution of Bipolar Depression in 2030

4. Disease Background and Overview: Bipolar Depression
4.1. Introduction
4.2. Classification of Bipolar Disorder According to DSM-5
4.3. Symptoms
4.4. Causes
4.5. Risk Factors
4.6. Pathophysiology
4.7. Genetics Findings in Bipolar Disorder
4.8. Biomarkers
4.9. Diagnosis
4.9.1. Diagnostic Guidelines

5. Case Reports
5.1. Bipolar II Disorder: Case Study
5.2. Clinical Characteristics and Legal Consequences of Violent Behavior: A Case of Bipolar Disorder
5.3. Effectiveness of Simple Individual Psychoeducation for Bipolar II Disorder

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. KOL Views
6.3. Epidemiology Methodology
6.4. Total Diagnosed Prevalent Cases of Bipolar Depression in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Diagnosed Prevalent Cases of Bipolar Depression in the United States
7.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the United States
7.4. Severity-specific Diagnosed Prevalent cases of Bipolar Depression in the United States

8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Diagnosed Prevalent Cases of Bipolar Depression in Germany
8.1.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany
8.1.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany
8.2. France Epidemiology
8.2.1. Assumptions and Rationale
8.2.2. Total Diagnosed Prevalent Cases of Bipolar Depression in France
8.2.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in France
8.2.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Total Diagnosed Prevalent Cases of Bipolar Depression in Italy
8.3.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy
8.3.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Diagnosed Prevalent Cases of Bipolar Depression in Spain
8.4.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain
8.4.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Total Diagnosed Prevalent Cases of Bipolar Depression in the UK
8.5.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK
8.5.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Total Diagnosed Prevalent Cases of Bipolar Depression in Japan
9.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan
9.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan

10. Current Treatment and Medical Practices
10.1. Treatment of Bipolar Disorder
10.1.1. Treatment Algorithm
10.1.2. Treatment Guideline

11. Unmet needs

12. Marketed Drugs
12.1. Vraylar (Cariprazine): Allergan (AbbVie)/Gedeon Richter
12.1.1. Product Description
12.1.2. Regulatory Milestones
12.1.3. Other Development Activities
12.1.4. Clinical Development
12.1.5. Safety and Efficacy
12.1.6. Product Profile
12.2. Latuda (Lurasidone Hydrochloride): Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Other Development Activities
12.2.4. Clinical Development
12.2.5. Safety and Efficacy
12.2.6. Product Profile

13. Emerging Drugs
13.1. Key Cross Competition
13.2. Abilify (Aripiprazole): Otsuka Pharmaceutical
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.2.5. Product Profile
13.3. Lumateperone/ITI-007: Intra-cellular Therapies
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Product Profile
13.4. NRX-100/NRX-101: NeuroRx
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Product Profile
13.5. Psilocybin: COMPASS Pathways
13.5.1. Product Description
13.5.2. Other Developmental Activities
13.5.3. Clinical Development
13.5.4. Product Profile
13.6. Zuranolone (SAGE-217): Sage Therapeutics
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Product Profile
13.7. SEP-4199: Sunovion/Sumitomo Dainippon Pharma
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Product Profile
13.8. ILT101: Iltoo Pharma
13.8.1. Product Description
13.8.2. Clinical Development
13.8.3. Product Profile
13.9. Falkieri (Esketamine DPI): Celon Pharma
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.4. Product Profile

14. Bipolar Depression: 7MM Market Analysis
14.1. Key Findings
14.2. Market Methodology
14.3. Attribute Analysis
14.4. Key Market Forecast Assumptions
14.5. Market Size of Bipolar Depression in the 7MM
14.6. Market Size of Bipolar Depression by Therapies in the 7MM

15. United States Market Outlook
15.1. United States Market Size
15.1.1. Total market size of Bipolar Depression in the United States
15.1.2. Market Size of Bipolar Depression by Therapies in the US

16. EU-5 Market Outlook
16.1. Germany Market Size
16.1.1. Total Market size of Bipolar Depression in Germany
16.1.2. Market Size of Bipolar Depression by therapies in Germany
16.2. France Market Size
16.2.1. Total Market size of Bipolar Depression in France
16.2.2. Market Size of Bipolar Depression by therapies in France
16.3. Italy Market Size
16.3.1. Total Market size of Bipolar Depression in Italy
16.3.2. Market Size of Bipolar Depression by therapies in Italy
16.4. Spain Market Size
16.4.1. Total Market size of Bipolar Depression in Spain
16.4.2. Market Size of Bipolar Depression by therapies in Spain
16.5. United Kingdom Market Size
16.5.1. Total Market size of Bipolar Depression in the United Kingdom
16.5.2. Market Size of Bipolar Depression by therapies in the UK

17. Japan Market Outlook
17.1. Japan Market Size
17.1.1. Total Market size of Bipolar Depression in Japan
17.1.2. Market Size of Bipolar Depression by therapies in Japan

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Reimbursement and Market Access

22. Appendix
22.1. Bibliography
22.2. Report Methodology

23. Publisher Capabilities

24. Disclaimer

25. About the Publisher

List of Tables
Table 1 Summary of Bipolar Depression, Market, Epidemiology and Key Events (2017–2030)
Table 2 Symptoms associated with manic and depressive episodes
Table 3 GWAS findings in bipolar disorder
Table 4 Main findings of circulating biomarkers in bipolar disorder
Table 5 Total Diagnosed Prevalent Cases of Bipolar Depression in the 7MM (2017–2030)
Table 6 Total Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)
Table 7 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)
Table 8 Severity-specific Diagnosed Prevalent cases of Bipolar Depression in the US (2017–2030)
Table 9 Total Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Table 10 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Table 11 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Table 12 Total Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Table 13 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Table 14 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Table 15 Total Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Table 16 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Table 17 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Table 18 Total Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Table 19 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Table 20 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Table 21 Total Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Table 22 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Table 23 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Table 24 Total Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Table 25 Total Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Table 26 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Table 27 Agents approved by the US FDA for acute bipolar mania, bipolar depression, and maintenance
Table 28 Categories of evidence (CE) and grade of recommendation (RG) for pharmacological and physical treatments used in acute Bipolar I depression (in alphabetical order within one category of evidence)
Table 29 Overall Recommendation Grades for long-term treatment
Table 30 Traditional evidence categories
Table 31 Vraylar (Cariprazine), Clinical Trial Description, 2020
Table 32 Vraylar (Cariprazine), Clinical Trial Description, 2020, Continued
Table 33 Latuda (Lurasidone Hydrochloride), Clinical Trial Description, 2020
Table 34 Latuda (Lurasidone Hydrochloride), Clinical Trial Description, 2020, Continued
Table 35 Key-Cross of Emerging Therapies
Table 36 Abilify (Aripiprazole), Clinical Trial Description, 2020
Table 37 Lumateperone (ITI-007), Patent Details
Table 38 Lumateperone (ITI-007), Clinical Trial Description, 2020
Table 39 NRX-100/NRX-101, Clinical Trial Description, 2020
Table 40 Psilocybin, Clinical Trial Description, 2020
Table 41 SAGE-217, Clinical Trial Description, 2020
Table 42 SEP-4199, Clinical Trial Description, 2020
Table 43 ILT101, Clinical Trial Description, 2020
Table 44 Falkieri (Esketamine), Clinical Trial Description, 2020
Table 45 Market Assumptions for Vraylar/Reagila
Table 46 Market Assumptions for Abilify
Table 47 Market Assumptions for Lumateperone/ITI-007
Table 48 Market Assumptions for NRX-100/NRX-101
Table 49 Market Assumptions for Zuranolone
Table 50 Market Assumptions for SEP-4199
Table 51 Market Assumptions for Falkieri
Table 52 Market Size of Bipolar Depression in the 7MM in USD Million (2017–2030)
Table 53 Market Size of Bipolar Depression by therapies in the 7MM, in USD Million (2017–2030)
Table 54 The US Market Size of Bipolar Depression in USD Million (2017–2030)
Table 55 Market Size of Bipolar Depression by therapies in the US, in USD Million (2017–2030)
Table 56 Germany Market Size of Bipolar Depression in USD Million (2017–2030)
Table 57 Market Size of Bipolar Depression by therapies in Germany, in USD Million (2017–2030)
Table 58 France Market Size of Bipolar Depression in USD Million (2017–2030)
Table 59 Market Size of Bipolar Depression by therapies in France, in USD Million (2017–2030)
Table 60 Italy Market Size of Bipolar Depression in USD Million (2017–2030)
Table 61 Market Size of Bipolar Depression by therapies in Italy, in USD Million (2017–2030)
Table 62 Spain Market Size of Bipolar Depression in USD Million (2017–2030)
Table 63 Market Size of Bipolar Depression by therapies in Spain, in USD Million (2017–2030)
Table 64 The UK Market Size of Bipolar Depression in USD Million (2017–2030)
Table 65 Market Size of Bipolar Depression by therapies in the UK, in USD Million (2017–2030)
Table 66 Japan Market Size of Bipolar Depression in USD Million (2017–2030)
Table 67 Market Size of Bipolar Depression by therapies in Japan, in USD Million (2017–2030)

List of Figures
Figure 1 Main subtypes of bipolar disorder
Figure 2 Symptoms of bipolar disorder
Figure 3 Effects of bipolar disorder on the body
Figure 4 Causes of bipolar disorder
Figure 5 Triggers in bipolar disorder
Figure 6 Multifactorial model of bipolar disorders
Figure 7 Symptoms with potential diagnostic utility in bipolar and unipolar depression
Figure 8 United States KOL Views
Figure 9 EU-5 and Japan KOL Views
Figure 10 Total Diagnosed Prevalent Cases of Bipolar Depression in the 7MM (2017–2030)
Figure 11 Total Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)
Figure 12 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)
Figure 13 Severity-specific Diagnosed Prevalent cases of Bipolar Depression in the US (2017–2030)
Figure 14 Total Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Figure 15 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Figure 16 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Figure 17 Total Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Figure 18 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Figure 19 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Figure 20 Total Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Figure 21 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Figure 22 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Figure 23 Total Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Figure 24 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Figure 25 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Figure 26 Total Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Figure 27 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Figure 28 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Figure 29 Total Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Figure 30 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Figure 31 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Figure 32 Algorithm for the Treatment of Mania/Hypomania
Figure 33 Algorithm for the Treatment of Depression in Bipolar Disorder*
Figure 34 Unmet needs
Figure 35 Market Size of Bipolar Depression in the 7MM in USD Million (2017–2030)
Figure 36 Market Size of Bipolar Depression by therapies in the 7MM, in USD Million (2017–2030)
Figure 37 Market Size of Bipolar Depression in the US, USD Millions (2017–2030)
Figure 38 Market Size of Bipolar Depression by therapies in the US, in USD Million (2017–2030)
Figure 39 Market Size of Bipolar Depression in Germany, USD Millions (2017–2030)
Figure 40 Market Size of Bipolar Depression by therapies in Germany, in USD Million (2017–2030)
Figure 41 Market Size of Bipolar Depression in France, USD Millions (2017–2030)
Figure 42 Market Size of Bipolar Depression by therapies in France, in USD Million (2017–2030)
Figure 43 Market Size of Bipolar Depression in Italy, USD Millions (2017–2030)
Figure 44 Market Size of Bipolar Depression by therapies in Italy in USD Million (2017–2030)
Figure 45 Market Size of Bipolar Depression in Spain, USD Millions (2017–2030)
Figure 46 Market Size of Bipolar Depression by therapies in Spain in USD Million (2017–2030)
Figure 47 Market Size of Bipolar Depression in the UK, USD Millions (2017–2030)
Figure 48 Market Size of Bipolar Depression by therapies in the UK in USD Million (2017–2030)
Figure 49 Market Size of Bipolar Depression in Japan, USD Millions (2017–2030)
Figure 50 Market Size of Bipolar Depression by therapies in Japan in USD Million (2017–2030)
Figure 51 Market Drivers
Figure 52 Market Barriers
Figure 53 SWOT analysis
Note: Product cover images may vary from those shown
  • Allergan (AbbVie)/Gedeon Richter
  • Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)
  • Otsuka Pharmaceutical
  • Intra-cellular Therapies
  • NeuroRx
  • COMPASS Pathways
  • Sage Therapeutics
  • Iltoo Pharma
  • Celon Pharma
Note: Product cover images may vary from those shown
Adroll
adroll